CLOV vs HUM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: HUM is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CLOV and HUM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CLOV and HUM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Clover Health Investments, Corp. is a US healthcare-technology company that offers Medicare Advantage plans, the private alternative to traditional Medicare, primarily to seniors. Unlike many rivals that lean on narrow-network HMO plans, Clover concentrates on wide-network PPO plans that let members see a broad range of doctors, which the company argues is a differentiator for seniors who value choice. At the heart of the business is Clover Assistant, a proprietary software platform that pulls together patient data and surfaces insights to physicians at the point of care, aiming to catch chronic conditions earlier and manage costs more effectively than a traditional insurer.

Full CLOV guide

Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covers roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.

Full HUM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CLOV drivers: Medicare Advantage membership growth; Path to profitability.
• HUM drivers: Demographic tailwind in Medicare Advantage; CenterWell healthcare services.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is that Clover is a small insurer competing against giants like UnitedHealth, Humana, CVS/Aetna, and Centene, which have far greater scale, capital, and provider leverage. For HUM, the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CLOV if you believe its drivers more; HUM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CLOV and HUM guides.

CLOV. All figures here are approximate and tied to the asOf date; verify live numbers before acting. For a fast-growing insurer, the medical-cost ratio (medical claims as a share of premiums), membership growth, and Star Ratings matter more than any single headline number, because small changes in medical costs can swing profitability sharply. Guidance and Star Ratings can be revised, so confirm the latest quarter and CMS status directly rather than relying on these approximations.

HUM. These figures are approximate and tied to the June 2026 asOf date; insurer earnings can move sharply quarter to quarter with the medical-cost trend, and the trailing P/E looks high mainly because recent profits are depressed. Check Humana's latest filings and a current quote before relying on any single number.

Headline figures (approximate, Jul 2026): CLOV shows medicare advantage membership ~150,000-plus members, up roughly 50% year over year into the 2026 plan year (approximate; verify live), 2026 revenue guidance Guided to the multi-billion-dollar range (roughly $2.8B to $2.9B midpoint framing; approximate), profitability Guided to positive adjusted EBITDA and first full-year GAAP net income profitability in 2026, 2026 cms star rating Main PPO contract raised to 4.5 stars (after a court order), covering the large majority of members; HUM shows revenue (ttm) ~$130 billion, adjusted eps (2026 guidance) ~$9.00 or more, medical loss ratio (2026 outlook) ~92.75%, dividend yield ~1.5%.

CLOV and HUM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CLOV and HUM exposure against your real portfolio. It is not an investment adviser.